Wendy Lim, McMaster University, Hamilton, ON
Low molecular weight heparins (LMWHs) have largely replaced unfractionated heparin (UFH) in many clinical settings. At the end of this session, participants will have a better understanding when LMWHs or UFH are used in patients. Also, participants will be informed on the latest available evidence of the used of LMWH with renally impaired patients with cancer.
Kathy Gesy, Saskatchewan Cancer Agency, Saskatoon, SK
Pedro Gascon, Barcelona University Medical School, Barcelona, Spain
- Examine the role of biomarkers and primary tumour location in treatment decisions, based on the latest clinical study findings;
- Review current guidance around the surgical management of mCRC, with a focus on resection of liver-limited metastases; and
- Recognize the elements of multidisciplinary care that are integral to achieving optimal outcomes for patients with mCRC.
- Examine the similarities and differences between innovator products and biosimilars, in terms of the manufacturing process and final product;
- Gain an understanding of the scientific evidence and regulatory requirements for marketing authorization of biosimilars; and
- Identify practical and clinical considerations for initiating or switching to a biosimilar, and the implications for patient management.
- Summarize the latest practice-changing evidence affecting the treatment of patients with metastatic melanoma or lung cancer under immunotherapy (monotherapy or combination);
- Discuss the role of pharmacists within an interdisciplinary team in recognizing and managing immuno-related toxicities; and
- Review best practices in the effective management of immuno-related AEs.
Karen Gelmon, Vancouver Centre, BCCA, Vancouver, BC
- Describe therapeutic approaches for the treatment of hormone-positive breast cancer: past history to the present day of endocrine therapy;
- Understand the implications of the evidence on patient management; and
- Discuss the impact of health and well-being initiatives on both patient and healthcare professionals.
- Review the historical outcomes in the pre-trastuzumab era, the trastuzumab revolution and optimization of trastuzumab therapy;
- Examine the role of novel agents/therapeutic strategies in early HER2-positive breast cancer;
- Understand the mechanism of action, common toxicities, and pharmacy consideration in administration of HER-targeted therapies; and
- Discuss the role of pharmacists in early breast cancer patient practice
- Describe the current regulatory environment in the US and Canada for pharmacies/pharmacists/technicians;
- Understand the major requirements of the USP Chapter <800>-Hazardous Drugs - Handling in the Healthcare Setting;
- Understand the major requirements of the NAPRA Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations; and
- Describe risk mitigation strategy to provide safe compounded medication while protecting healthcare workers.
- Describe the prevalence of fatigue in oncology patients and how it impacts patient quality of life using a hormonal oral agent case example;
- Discuss exercise-based strategies to improve the management of fatigue in oncology patients and review data on the impact of physical activity on patient quality of life; and
- Recognize the role of pharmacists in counselling patients, monitoring fatigue, and the importance of collaboration with other HCPs to optimize patient management.
Marshall Moleschi, Ontario College of Pharmacists, Toronto, ON
- Describe how the standards were designed with an in-depth knowledge of the Canadian Healthcare Model;
- What Canadian patient’s and Health Care workers expect, with consideration of the service areas from urban, to rural to remote;
- How the NAPRA model standards will evolve; and
- Strategies for being compliant and meeting the standards within your operating budget.